Patents by Inventor Roman M. Chicz
Roman M. Chicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016918Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.Type: ApplicationFiled: August 23, 2021Publication date: January 18, 2024Applicant: SANOFI PASTEUR INC.Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
-
Publication number: 20110158952Abstract: The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to a the age of the recipient, as well as the use of the composition to elicit a cross-reactive anti-HPV immune response.Type: ApplicationFiled: June 7, 2010Publication date: June 30, 2011Applicant: EISAI INC.Inventors: Kathleen Beach, Mary Lynne Hedley, Robert G. Urban, Roman M. Chicz
-
Patent number: 7408031Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: February 2, 2007Date of Patent: August 5, 2008Assignees: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7408029Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: February 2, 2007Date of Patent: August 5, 2008Assignees: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7173108Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: March 3, 2003Date of Patent: February 6, 2007Assignees: MGI Pharma Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7097843Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: June 24, 2003Date of Patent: August 29, 2006Assignee: MGI Pharma Biologics, Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Publication number: 20040236091Abstract: Polypeptides representative of proteins expressed by a given cell type and isolated nucleic acids that encode the polypeptides are disclosed. The compositions and method described can be used to define a cell type at a given developmental, metabolic, or disease stage by identifying and cataloging proteins expressed in the cell. The compositions can also be used in the manufacture of therapeutics as well as in diagnostics and drug screening.Type: ApplicationFiled: June 17, 2004Publication date: November 25, 2004Inventors: Roman M. Chicz, Andrew J. Tomlinson, Robert G. Urban
-
Publication number: 20040229809Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: ApplicationFiled: June 24, 2003Publication date: November 18, 2004Applicant: Zycos Inc., a Delaware corporationInventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Publication number: 20040224338Abstract: An expressed protein tag (EPT) profile characteristic for a given cell, the profile including a representation of at least ten different polypeptides expressed by the cell and bound by a given type of multi-ligand binding receptor; and computer-assisted manipulation of such a profile.Type: ApplicationFiled: March 24, 2004Publication date: November 11, 2004Applicant: Zycos Inc., a Delaware corporationInventors: Roman M. Chicz, Mary Lynne Hedley, Charles Hsu, Robert G. Urban
-
Publication number: 20040071726Abstract: The invention provides methods for identifying and validating epitopes that are bound to class II MHC molecules and activate CD4+ T cells involved in the pathogenesis of or protection from diseases, e.g., cancer. The invention includes peptide epitopes (including altered peptide ligands) derived from the CEA polypeptide by such methods, and methods of therapeutic use of these epitopes against diseases such as cancers.Type: ApplicationFiled: June 13, 2003Publication date: April 15, 2004Inventors: Roman M. Chicz, Andy Tomlinson
-
Patent number: 6696061Abstract: A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.Type: GrantFiled: June 15, 1993Date of Patent: February 24, 2004Assignee: President and Fellows of Harvard CollegeInventors: Robert Glen Urban, Roman M. Chicz, Dario A. A. Vignali, Mary Lynne Hedley, Lawrence J. Stern, Jack L. Strominger
-
Publication number: 20040006202Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: ApplicationFiled: March 3, 2003Publication date: January 8, 2004Applicants: Zycos, Inc. a Delaware corporation, King's College London, an institution incorporated by Royal Charter in EnglandInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 6582704Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: January 12, 2001Date of Patent: June 24, 2003Assignee: Zycos Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Patent number: 6562943Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: April 20, 2000Date of Patent: May 13, 2003Assignees: Zycos, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 6509033Abstract: A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.Type: GrantFiled: June 7, 1995Date of Patent: January 21, 2003Assignee: President and Fellows of Harvard CollegeInventors: Robert Glen Urban, Roman M. Chicz, Dario A. A. Vignali, Mary Lynne Hedley, Lawrence J. Stern, Jack L. Strominger
-
Publication number: 20020155614Abstract: The invention provides methods and reagents for the esterification of peptides. The methods can be used to (i) enable a peptide in a first sample to be quantified relative to the level of the same peptide in a second sample, (ii) identify peptides in a complex mixtures that are targets for sequencing efforts, and (iii) aid peptide sequence elucidation. Methods that promote esterification and the formation of esters that are labeled with stable isotopes are described. These methods are useful for the analysis of low concentration (e.g., sub-femtomole) peptide mixtures.Type: ApplicationFiled: February 21, 2002Publication date: October 24, 2002Inventors: Andrew J. Tomlinson, Marina Hincapie, Roman M. Chicz
-
Patent number: 6183746Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: October 9, 1998Date of Patent: February 6, 2001Assignee: Zycos Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Patent number: 6013258Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: October 9, 1997Date of Patent: January 11, 2000Assignee: Zycos Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Patent number: 5880103Abstract: A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.Type: GrantFiled: June 7, 1995Date of Patent: March 9, 1999Assignee: President and Fellows of Harvard CollegeInventors: Robert Glen Urban, Roman M. Chicz, Dario A. A. Vignali, Mary Lynne Hedley, Lawrence J. Stern, Jack L. Strominger
-
Patent number: 5827516Abstract: A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.Type: GrantFiled: June 7, 1995Date of Patent: October 27, 1998Assignee: President and Fellows of Harvard CollegeInventors: Robert Glen Urban, Roman M. Chicz, Dario A. A. Vignali, Mary Lynne Hedley, Lawrence J. Stern, Jack L. Strominger